Skip to main content
TipRanks
Go Ultimate75% OFF

Acarix AB (ACARIX) AI Stock Analysis

3 Followers
SE:ACARIX

Acarix AB

(Nasdaq OMX AB:ACARIX)

Select Model
Rating:41Neutral
Price Target:SEK 0.15â–¼(-8.13% Downside)
Action:upgraded
Date:11/13/26

The overall score is heavily pressured by severe unprofitability and negative cash flows, which overshadow strong revenue growth. Technicals confirm a persistent downtrend, and the negative P/E ratio offers no valuation support. The debt-free balance sheet is the sole mitigating factor, but it is being rapidly consumed by ongoing losses.

Positive Factors
Improving revenue and gross marginImproving revenue alongside a materially higher gross margin indicates better unit economics and growing commercial traction. If maintained, this combination can support stronger contribution from each sale and provide a foundation for operating leverage as the business expands its customer base.
Negative Factors
Severe operating lossesThe scale of current operating and net losses remains the central fundamental weakness. Such deeply negative margins show that revenue is not yet sufficient to cover the cost base, making profitability dependent on substantial improvement in scale, pricing, or operating efficiency.

Acarix AB (ACARIX) vs. iShares MSCI Sweden ETF (EWD)

-60%-40%-20%0%20%40%SE:ACARIX-50.00%EWD+8.63%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 191.04M
Dividend Yield
―
Average Volume (3M)
1.48M
Price to Earnings (P/E)
-5.0
Beta (1Y)
0.18
Revenue Growth
40.61%
EPS Growth
32.63%
Country
Sweden
Employees
8
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Acarix AB Business Overview & Revenue Model

Company Description

Acarix AB (publ) is a medical technology company that develops and introduces diagnostic solutions for cardiovascular conditions to markets including Germany, Sweden, the Middle East, Switzerland, Austria, and globally. Their key product is the CADSc...

Acarix AB Financial Statement Overview

Summary

Strong 5.5x revenue growth and improving gross margins to 48.8% are offset by deep unprofitability (TTM net margin -387%) and substantial cash burn. The debt-free balance sheet provides a cushion, but equity is eroding rapidly with a -96.1% ROE, making the overall financial health precarious.

Income Statement

35Negative

Balance Sheet

65Positive

Cash Flow

30Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue9.73M7.36M6.20M6.24M5.82M3.76M
Gross Profit4.75M2.76M5.59M5.30M4.62M2.82M
EBITDA-33.84M-44.53M-62.63M-74.62M-73.78M-48.28M
Net Income-37.67M-48.09M-66.19M-77.84M-76.98M-51.80M
Balance Sheet
Total Assets41.41M48.33M80.76M62.88M69.48M118.60M
Cash, Cash Equivalents and Short-Term Investments21.00M18.27M53.99M35.15M11.31M15.81M
Total Debt0000251.00K523.00K
Total Liabilities3.43M10.16M5.06M11.00M17.66M18.06M
Stockholders Equity37.98M38.17M75.70M51.88M51.83M100.54M
Cash Flow
Free Cash Flow-24.04M-49.14M-64.25M-81.37M-75.02M-48.05M
Operating Cash Flow-35.79M-48.38M-63.33M-81.37M-74.87M-48.01M
Investing Cash Flow-233.00K-757.00K-920.00K0-151.00K-43.00K
Financing Cash Flow31.89M11.11M86.98M106.23M69.03M-164.00K

Acarix AB Technical Analysis

Technical Analysis SentimentNegative
Last Price0.16

Price Trends

50DMA0.19Negative
100DMA0.22Negative
200DMA0.25Negative

Market Momentum

MACD-0.01Positive
RSI37.21Neutral
STOCH41.52Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACARIX, the sentiment is Negative. The current price of 0.16 is below the 20-day moving average (MA) of 0.17, below the 50-day MA of 0.19, and below the 200-day MA of 0.25, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 37.21 is Neutral, neither overbought nor oversold. The STOCH value of 41.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ACARIX.

Acarix AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:ACARIX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:SECT.BSE:SECT.B64NeutralSEK 65.68B100.9830.26%0.70%13.94%5.70%
SE:SEZISE:SEZI55NeutralSEK 518.02M-5.23-35.44%―18.56%28.11%
SE:BACTI.BSE:BACTI.B53NeutralSEK 529.16M82.501.93%―-0.51%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:MNTCSE:MNTC51NeutralSEK 462.67M-24.43-15.00%―11.18%60.51%
SE:HEARTSE:HEART47NeutralSEK 132.57M-2.15-54.68%―――
SE:ACARIXSE:ACARIX41NeutralSEK 191.04M-5.03-96.06%―40.61%32.63%

* Healthcare Sector Average

Performance Comparison

-50%0%50%SE:ACARIXSE:SEZISE:BACTI.BSE:SECT.BSE:HEARTSE:MNTCDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:ACARIX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:ACARIXAcarix AB0.16-0.14-47.19%
SE:SEZISenzime AB3.25-1.81-35.87%
SE:BACTI.BBactiguard Holding AB14.85-1.50-9.17%
SE:SECT.BSectra AB Class B330.2047.0616.62%
SE:HEARTScandinavian Real Heart AB15.201.7512.99%
SE:MNTCMentice AB16.401.308.61%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026